抗菌藥物：全球市場展望 2012-2022

抗菌藥物：全球市場展望 2012-2022 是由出版商Visiongain在2011年11月所出版的。 這份英文市場調查報告書包含167 Pages 價格從美金2642起跳。

簡介

本報告為，關注抗菌治療藥物市場，並匯整全球及主要國家本市場於2022年止之10年間收益成長預測、目前主要產品及製藥商趨勢、提升抗菌效妥之新藥開發現況等最新調查資訊，以下列摘要形式闡述。

第1章 實施概要

• 抗菌藥物：全球市場探討
• 各章概要
• 調查及分析方式

第2章 細菌、細菌感染、抗菌藥物簡介

• 細菌、細菌感染
  • 細菌
  • 臨床上重要細菌
  • 細菌感染
• 抗菌藥物
  • 抗菌藥物之歷史
  • 抗菌藥物之作用機制

第3章 抗菌藥物市場 2012-2022

• 抗菌藥物市場 2010-2011
• 抗菌藥物市場：總收益預測 2012-2022
• 頭孢菌素市場 2010-2011
• 青黴素市場 2010-2011
• 氟喹諾酮市場 2010-2011
• 大環內酯類市場 2010-2011
• 碳青黴烯類市場 2010-2011
• 其他抗菌藥物市場 2010-2011

第4章 主要抗菌藥物產品：市場展望 -2022

• 主要抗菌藥物概要
• Levaquin
• Zyvox
• Avelox
• Augmentin
• Zosyn
• Merrem
• Cubicin
• Primaxin
• Biaxin
• Cravit
• Zithromax
• Invanz
• Cipro
• Tygacil
• Rocephin
• Zinnat
• Flomox
• Unasyn
• Dalacin C
• Meiact

第5章 主要國家之抗菌藥物市場 2012-2022

• 主要國家市場 2010-2021
• 主要國家市場：收益預測 2012-2022
• 歐洲市場：收益預測 2012-2022
• 美國：收益預測 2012-2022
• 中國：收益預測 2012-2022
• 日本：收益預測 2012-2022
• 印度：收益預測 2012-2022
• 巴西：收益預測 2012-2022

第6章 抗菌藥物R&D產品線 2011

• Zinforo（Ceftaroline、AstraZeneca/Forest Laboratories）
• Ceftobiprole（Basilea Pharmaceutica）
• Restanza（Cethromycin、Advanced Life Sciences）：後續開發產品為何？
• Dalbavancin（Durata Therapeutics）
• Nuvocid（Oritavancin, The Medicines Company）
• TR-701（Tedizolid、Trius Therapeutics）
• CAZ104（Ceftazidime/Avibactam、AstraZeneca/Forest Laboratories）
  • CEF104（Ceftaroline/Avibactam、AstraZeneca/Forest Laboratories）
• CXA-201（Cubist）
• NKTR-061（Amikacin Inhalation、Bayer/Nektar Therapeutics）
• Ramoplanin（Nanotherapeutics）
• Radezolid（Rib-X Pharmaceuticals）

第7章 抗菌藥物：產業趨勢

• 2011年抗菌藥物市場之強項及弱點
• 2012-2022年抗菌藥物市場之機會及威脅
• 後期產品線治療
• 新策略
• 細菌耐藥性：機會及威脅
• 非劣性研究之難關
• 改善後之法規指標
• 週期管理
• 院內感染

第8章 訪問調查

• Basilea Pharmaceutica公司生物部長、Professor Malcolm Page
• Kenta Biotech社CSO、Dr Michael Rudolf

第9章 本調查結論

• 抗菌藥物市場 2012-2022
  • 主要產品之銷售表現 2012-2022
• R&D產品線：未來展望
• 細菌耐藥性：新挑戰

專業用語：臨床細菌學

圖表一覽

企業索引

目錄

Abstract

Report Details

What are the commercial prospects for antibacterial treatments? Visiongain's report shows you potential revenue values to 2022. Find data, forecasts and discussions.

Discover sales predictions at world market, therapeutic class, product and national levels to 2022. Our report gives you business research, analysis and opinion for the treatment of bacterial infections.

How will 20 leading products - including Levaquin, Zyvox, Avelox, Augmentin, Zosyn, Merrem, Cubicin, Primaxin and Cravit - perform to 2022? You can find potential revenues, with discussions.

Also, receive forecast values for cephalosporin, penicillin, fluoroquinolone, macrolide and carbapenem submarkets. We analyse other agents too. See possible sales trends for antibiotics from 2012.

This study discusses Pfizer, Merck, GSK, Cubist, Abbott, Bayer and other pharmaceutical companies. Receive analyses for anti-infective agents in human healthcare, including hospital-acquired infections.

What does the future hold? With its R&D pipeline, the antimicrobial drug industry has potential for improved treatment of bacterial diseases. Bacteria still pose a great threat, with antibiotic resistance staying a challenge in clinical practice.

Visiongain's report provides data, analysis and opinion aiming to benefit your research, calculations, meetings and presentations. You can find answers now in our work.

Revenue forecasts, market shares, developmental trends, discussions and interviews

In our report, you find revenue forecasting, growth rates, market shares, qualitative analyses (incl. SWOT and STEP), views and R&D news. You receive 149 tables and charts and two research interviews.

Advantages of Antibacterial Drugs: World Market Prospects 2012-2022 for your work

In particular, our study gives you the following knowledge and benefits:

• Find revenue predictions to 2022 for the overall world antibacterial drug market and submarkets, seeing revenue growth
• Discover revenue forecasts to 2022 for 20 leading products, assessing commercial potential
• See revenue forecasts to 2022 for leading national markets - US, Japan, China, India, Brazil, France, Italy, Germany, UK and Spain
• Assess leading companies, discovering their activities and prospects
• Review R&D for treating bacterial diseases, seeing pipeline trends
• Investigate competition and opportunities influencing the sector and its sales
• Find out what will stimulate and restrain the industry and market
• View opinions from our survey, discovering interviews with industrial experts.

There, you find a distinctive mix of quantitative and qualitative work with independent predictions. We tackle crucial questions on antibacterials, helping you to stay ahead.

Table of Contents

1. Executive Summary

• 1.1 Antibacterial Drugs: World Market Review
• 1.2 Chapter Breakdown
• 1.3 Research and Analysis Methods

2. An Introduction to Bacteria, Bacterial Infections and Antibacterial Drugs

• 2.1 Bacteria and Bacterial Infections
  • 2.1.1 Bacteria
  • 2.1.2 Clinically Important Bacteria
  • 2.1.3 Bacterial Infections
    • 2.1.3.1 Bacteria's Infectious Activity
• 2.2 Antibacterial Drugs
  • 2.2.1 A History of Antibacterial Drugs
    • 2.2.1.1 Penicillin
    • 2.2.1.2 Other Key Steps in the History of Antibacterial Drugs
  • 2.2.2 Mechanisms of Action for Antibacterial Drugs

3. The Antibacterial Drugs Market 2012-2022

• 3.1 The Antibacterial Drugs Market 2010-2011
• 3.2 The Antibacterial Drugs Market: Overall Revenue Forecast 2012-2022
  • 3.2.1 Generic Competition
  • 3.2.2 Prescribing Antibacterial Drugs
  • 3.2.3 Bacterial Resistance
  • 3.2.4 R&D Pipeline Will Restrain Growth?
• 3.3 Cephalosporins Submarket 2010-2011
  • 3.3.1 Cephalosporins Submarket: Revenue Forecast 2012-2022
• 3.4 Penicillin Submarket 2010-2011
  • 3.4.1 Penicillins Submarket: Revenue Forecast 2012-2022
• 3.5 Fluoroquinolone Submarket 2010-2011
  • 3.5.1 Fluoroquinolones are Linked with Side Effects
  • 3.5.2 Fluoroquinolone Pipeline 2011
  • 3.5.3 Fluoroquinolone Submarket: Revenue Forecast 2012-2022
• 3.6 Macrolide Submarket 2010-2011
  • 3.6.1 Dificid: A New Macrolide
  • 3.6.2 Macrolide Submarket: Revenue Forecast 2012-2022
• 3.7 Carbapenems Submarket 2010-2011
  • 3.7.1 Doribax (Doripenem, Ortho-McNeil/Shionogi)
  • 3.7.2 Carbapenems Submarket: Revenue Forecast 2012-2022
• 3.8 Other Antibacterial Drugs Submarket 2010-2011
  • 3.8.1 Vibativ
  • 3.8.2 Other Antibacterial Drugs Submarket: Revenue Forecast 2012-2022

4. Leading Antibacterial Drugs: Market Prospects to 2022

• 4.1 Leading Antibacterial Drugs Overview
• 4.2 Levaquin
  • 4.2.1 Levaquin: Revenue Forecast 2012-2022
• 4.3 Zyvox
  • 4.3.1 Zyvox: Revenue Forecast 2012-2022
• 4.4 Avelox
  • 4.4.1 Avelox: Revenue Forecast 2012-2022
• 4.5 Augmentin
  • 4.5.1 Augmentin: Revenue Forecast 2012-2022
• 4.6 Zosyn
  • 4.6.1 Zosyn: Revenue Forecast 2012-2022
• 4.7 Merrem
  • 4.7.1 Merrem: Revenue Forecast 2012-2022
• 4.8 Cubicin
  • 4.8.1 Cubicin: US Revenue Forecast 2012-2022
• 4.9 Primaxin
  • 4.9.1 Primaxin: Revenue Forecast 2012-2022
• 4.10 Biaxin
• 4.11 Cravit
  • 4.11.1 Cravit: Revenue Forecast 2012-2022
• 4.12 Zithromax
• 4.13 Invanz
  • 4.13.1 Invanz: Revenue Forecast 2012-2022
• 4.14 Cipro
• 4.15 Tygacil
  • 4.15.1 Tygacil: Revenue Forecast 2012-2022
• 4.16 Rocephin
  • 4.16.1 Rocephin: Revenue Forecast 2012-2022
• 4.17 Zinnat
• 4.18 Flomox
• 4.19 Unasyn
• 4.20 Dalacin C
• 4.21 Meiact

5. Leading National Antibacterial Drug Markets 2012-2022

• 5.1 Leading National Markets 2010-2011
• 5.2 Leading National Markets: Revenue Forecasts 2012-2022
• 5.3 The European Market: Revenue Forecasts 2012-2022
• 5.4 The US: Revenues 2012-2022
• 5.5 China: Revenues 2012-2022
• 5.6 Japan: Revenues 2012-2022
• 5.7 India: Revenues 2012-2022
• 5.8 Brazil: Revenues 2012-2022

6. Antibacterial Drugs R&D Pipeline in 2011

• 6.1 Zinforo (Ceftaroline, AstraZeneca/Forest Laboratories)
• 6.2 Ceftobiprole (Basilea Pharmaceutica)
• 6.3 Restanza (Cethromycin, Advanced Life Sciences): Any Future Development?
• 6.4 Dalbavancin (Durata Therapeutics)
• 6.5 Nuvocid (Oritavancin, The Medicines Company)
• 6.6 TR-701 (Tedizolid, Trius Therapeutics)
• 6.7 CAZ104 (Ceftazidime/Avibactam, AstraZeneca/Forest Laboratories)
  • 6.7.1 CEF104 (Ceftaroline/Avibactam, AstraZeneca/Forest Laboratories)
• 6.8 CXA-201 (Cubist)
• 6.9 NKTR-061 (Amikacin Inhalation, Bayer/Nektar Therapeutics)
• 6.10 Ramoplanin (Nanotherapeutics)
• 6.11 Radezolid (Rib-X Pharmaceuticals)

7. Antibacterial Drugs: Industry Trends 2012-2022

• 7.1 Strengths and Weaknesses in the Antibacterial Drugs Market 2011
• 7.2 Opportunities and Threats in the Antibacterial Drugs Market 2012-2022
• 7.3 Late-Stage Pipeline Therapies
  • 7.3.1 Governmental Incentives
• 7.4 New Strategies
  • 7.4.1. Monoclonal Antibodies
  • 7.4.2 Inhaled Antibiotics for Hospital-Acquired Pneumonia
• 7.5 Bacterial Resistance: An Opportunity and a Threat
  • 7.5.1 Emerging Resistance
  • 7.5.2 Restricting Drug Use
• 7.6 The Challenge of Non-Inferiority Trials
• 7.7 Improved Regulatory Guidance
• 7.8 Lifecycle Management
• 7.9 Hospital-Acquired Infections
  • 7.9.1 Treating Hospital-Acquired Infections
  • 7.9.2 Preventing Hospital-Acquired Infections
  • 7.9.3 Hospital Hygiene
  • 7.9.4 Tracking Infections
  • 7.9.5 Advances in Hospital Equipment
    • 7.9.5.1 Copper Kills Bacteria

8. Research Interviews8.1 Professor Malcolm Page, Head of Biology, Basilea Pharmaceutica

• 8.1 Professor Malcolm Page, Head of Biology, Basilea Pharmaceutica
  • 8.1.1 Basilea Pharmaceutica
  • 8.1.2 Antibacterial Research This Decade
  • 8.1.3 Challenges in Developing Treatments for Gram-Negative Bacteria
  • 8.1.4 Overcoming Drug Resistance
  • 8.1.5 New Targets for Antibacterial Drug Development
• 8.2 Dr Michael Rudolf, CSO, Kenta Biotech
  • 8.2.1 Kenta Biotech
  • 8.2.2 Monoclonal Antibodies for Bacterial Infections
  • 8.2.3 Challenges in Developing Treatments for Gram-Negative Bacteria
  • 8.2.4 Unmet Needs in the Antibacterial Drugs Market

9. Conclusions from Our Study

• 9.1 Antibacterial Drugs Market 2012-2022
  • 9.1.1 Leading Product Performance 2012-2022
• 9.2 The R&D Pipeline: Outlook for the Future
• 9.3 Bacterial Resistance: a Rising Challenge

Other Content

Glossary: Clinical Bacteriology

List of Tables

• Table 1.1 Currency Exchange Rates
• Table 1.2 Common Abbreviations Used in this Report
• Table 2.1 Common Causes of Hospital-Acquired Infections Worldwide, 2011
• Table 2.2 Examples of Clinically-Important Bacteria, 2011
• Table 2.3 Mechanism of Action for Leading Antibacterial Drug Classes
• Table 3.1 Antibacterial Drugs Market by Class, 2010
• Table 3.2 Antibacterial Drugs Market: Overall Market and Revenue Forecasts by Class, 2010-2022
• Table 3.3 Antibacterial Drugs Market: Drivers and Restraints, 2012-2022
• Table 3.4 Antibacterial Drugs: Submarket Shares, 2010-2022
• Table 3.5 Cephalosporins Submarket: Drug Revenues, 2010
• Table 3.6 Cephalosporins Submarket: Revenue Forecast, 2010-2022
• Table 3.7 Cephalosporins Submarket: Drivers and Restraints, 2012-2022
• Table 3.8 Penicillins Submarket: Drug Revenues, 2010
• Table 3.9 Penicillins Submarket: Drivers and Restraints, 2012-2022
• Table 3.10 Penicillins Submarket: Revenue Forecast, 2010-2022
• Table 3.11 Fluoroquinolones Submarket: Drug Revenues, 2010
• Table 3.12 Penicillins Submarket: Drivers and Restraints, 2012-2022
• Table 3.13 Fluoroquinolones Submarket: Revenue Forecast, 2010-2022
• Table 3.14 Macrolides Submarket: Drug Revenues, 2010
• Table 3.15 Macrolides Submarket: Drivers and Restraints, 2012-2022
• Table 3.16 Macrolides Submarket: Revenue Forecast, 2010-2022
• Table 3.17 Carbapenems Submarket: Drug Revenues, 2010
• Table 3.18 Carbapenems Submarket: Drivers and Restraints, 2012-2022
• Table 3.19 Carbapenems Submarket: Revenue Forecast, 2010-2022
• Table 3.20 Other Antibacterial Drugs Submarket: Drug Revenues, 2010
• Table 3.21 Other Antibacterial Drugs Submarket: Revenue Forecast, 2010-2022
• Table 4.1 Top 20 Antibacterial Drugs, 2010
• Table 4.2 2010 Top 20 Antibacterial Drugs: Revenue Forecast, 2010-2022
• Table 4.3 Levaquin Key Facts, 2011
• Table 4.4 Levaquin: Revenue Forecast, 2010-2022
• Table 4.5 Zyvox Key Facts, 2011
• Table 4.6 Zyvox: Nine-Month Revenue, 2010-2011
• Table 4.7 Zyvox: Revenue Forecast, 2010-2022
• Table 4.8 Avelox Key Facts, 2011
• Table 4.9 Avelox: Six-Month Revenue by Company, 2010-2011
• Table 4.10 Avelox: Revenue Forecast, 2010-2022
• Table 4.11 Augmentin Key Facts, 2011
• Table 4.12 Augmentin: Revenue Forecast, 2010-2022
• Table 4.13 Zosyn Key Facts, 2011
• Table 4.14 Zosyn: Nine-Month Revenue, 2010-2011
• Table 4.15 Zosyn: Revenue Forecast, 2010-2022
• Table 4.16 Merrem Key Facts, 2011
• Table 4.17 Merrem: Nine-Month Revenue, 2010-2011
• Table 4.18 Merrem: Revenue Forecast, 2010-2022
• Table 4.19 Cubicin Key Facts, 2011
• Table 4.20 Cubicin: Nine-Month Revenue, 2010-2011
• Table 4.21 Cubicin: Revenue Forecast, 2010-2022
• Table 4.22 Primaxin Key Facts, 2011
• Table 4.23 Primaxin: Revenue Forecast, 2010-2022
• Table 4.24 Biaxin Key Facts, 2011
• Table 4.25 Biaxin: Revenue Forecast, 2010-2022
• Table 4.26 Cravit Key Facts, 2011
• Table 4.27 Cravit: Revenue, Fiscal Years 2006-2011
• Table 4.28 Cravit: Revenue Forecast, 2010-2022
• Table 4.29 Zithromax Key Facts, 2011
• Table 4.30 Zithromax: Nine-Month Revenue, 2010-2011
• Table 4.31 Zithromax: Revenue Forecast, 2010-2022
• Table 4.32 Invanz Key Facts, 2011
• Table 4.33 Invanz: Six-Month Revenue, 2010-2011
• Table 4.34 Invanz: Revenue Forecast, 2010-2022
• Table 4.35 Cipro Key Facts, 2011
• Table 4.36 Cipro: Revenue Forecast, 2010-2022
• Table 4.37 Tygacil Key Facts, 2011
• Table 4.38 Tygacil: Nine-Month Revenue, 2010-2011
• Table 4.39 Tygacil: Revenue Forecast, 2010-2022
• Table 4.40 Rocephin Key Facts, 2011
• Table 4.41 Rocephin: Revenue Forecast, 2010-2022
• Table 4.42 Zinnat Key Facts, 2011
• Table 4.43 Zinnat: Revenue Forecast, 2010-2022
• Table 4.44 Flomox Key Facts, 2011
• Table 4.45 Flomox: Revenue Forecast, 2010-2022
• Table 4.46 Unasyn Key Facts, 2011
• Table 4.47 Unasyn: Revenue Forecast, 2010-2022
• Table 4.48 Dalacin C Key Facts, 2011
• Table 4.49 Dalacin C: Revenue Forecast, 2010-2022
• Table 4.50 Meiact Key Facts, 2011
• Table 4.51 Meiact: Revenue Forecast, 2010-2022
• Table 5.1 Antibacterial Drugs Market by Region, 2010
• Table 5.2 Antibacterial Drugs Market: Revenue Forecasts by Region, 2010-2022
• Table 5.3 European Antibacterial Drugs Market by Country, 2010
• Table 5.4 European Antibacterial Drugs Market: Revenue Forecasts by Country, 2010-2022
• Table 6.1 Selected Antibacterial Pipeline Candidates Discussed
• Table 6.2 Selected Antibacterial Pipeline Candidates Not Discussed
• Table 7.1 Antibacterial Drugs Market: Strength and Weaknesses, 2011
• Table 7.2 Antibacterial Drugs Market: Opportunities and Threats, 2012-2022
• Table 7.3 Selected Inhaled Antibiotics in Development, 2011
• Table 9.1 Antibacterial Drugs Market: Revenues by Class, 2010, 2016 and 2022
• Table 9.2 Fate of the 2010 Top 20 Antibacterial Drugs: Combined Revenues, 2010, 2016 and 2022

List of Figures

• Figure 2.1 Milestones in the History of Antibacterial Agents, 1940-2011
• Figure 3.1 Antibacterial Drugs: Market Shares by Class, 2010
• Figure 3.2 Antibacterial Drugs Market: Overall Market and Revenue Forecasts by Class, 2010-2022
• Figure 3.3 Antibacterial Drugs: Market Shares by Class, 2016
• Figure 3.4 Antibacterial Drugs: Market Shares by Class, 2022
• Figure 3.5 Cephalosporins Submarket: Market Shares, 2010
• Figure 3.6 Cephalosporins Submarket: Revenue Forecast, 2010-2022
• Figure 3.7 Penicillins Submarket: Market Shares, 2010
• Figure 3.8 Penicillins Submarket: Revenue Forecast, 2010-2022
• Figure 3.9 Fluoroquinolones Submarket: Market Shares, 2010
• Figure 3.10 Fluoroquinolones Submarket: Revenue Forecast, 2010-2022
• Figure 3.11 Macrolides Submarket: Market Shares, 2010
• Figure 3.12 Macrolides Submarket: Revenue Forecast, 2010-2022
• Figure 3.13 Carbapenems Submarket: Market Shares, 2010
• Figure 3.14 Carbapenems Submarket: Revenue Forecast, 2010-2022
• Figure 3.15 Other Antibacterial Drugs Submarket: Market Shares, 2010
• Figure 3.16 Other Antibacterial Drugs Submarket: Revenue Forecast, 2010-2022
• Figure 4.1 Top 20 Antibacterial Drugs, 2010
• Figure 4.2 2010 Top 20 Antibacterial Drugs: Grouped Revenue Forecast, 2010-2022
• Figure 4.3 Levaquin: Revenue Forecast, 2010-2022
• Figure 4.4 Zyvox: Nine-Month Revenue, 2010-2011
• Figure 4.5 Zyvox: Revenue Forecast, 2010-2022
• Figure 4.6 Avelox: Six-Month Revenue by Company, 2010-2011
• Figure 4.7 Avelox: Revenue Forecast, 2010-2022
• Figure 4.8 Augmentin: Revenue Forecast, 2010-2022
• Figure 4.9 Zosyn: Nine-Month Revenue, 2010-2011
• Figure 4.10 Zosyn: Revenue Forecast, 2010-2022
• Figure 4.11 Merrem: Nine-Month Revenue, 2010-2011
• Figure 4.12 Merrem: Revenue Forecast, 2010-2022
• Figure 4.13 Cubicin: Nine-Month Revenue, 2010-2011
• Figure 4.14 Cubicin: Revenue Forecast, 2010-2022
• Figure 4.15 Primaxin: Revenue Forecast, 2010-2022
• Figure 4.16 Biaxin: Revenue Forecast, 2010-2022
• Figure 4.17 Cravit: Revenue, Fiscal Years 2006-2011
• Figure 4.18 Cravit: Revenue Forecast, 2010-2022
• Figure 4.19 Zithromax: Nine-Month Revenue, 2010-2011
• Figure 4.20 Zithromax: Revenue Forecast, 2010-2022
• Figure 4.21 Invanz: Six-Month Revenue, 2010-2011
• Figure 4.22 Invanz: Revenue Forecast, 2010-2022
• Figure 4.23 Cipro: Revenue Forecast, 2010-2022
• Figure 4.24 Tygacil: Nine-Month Revenue, 2010-2011
• Figure 4.25 Tygacil: Revenue Forecast, 2010-2022
• Figure 4.26 Rocephin: Revenue Forecast, 2010-2022
• Figure 4.27 Zinnat: Revenue Forecast, 2010-2022
• Figure 4.28 Flomox: Revenue Forecast, 2010-2022
• Figure 4.29 Unasyn: Revenue Forecast, 2010-2022
• Figure 4.30 Dalacin C: Revenue Forecast, 2010-2022
• Figure 4.31 Meiact: Revenue Forecast, 2010-2022
• Figure 5.1 Antibacterial Drugs Market Shares by Region, 2010
• Figure 5.2 Antibacterial Drugs Market Shares by Region, 2016
• Figure 5.3 Antibacterial Drugs Market Shares by Region, 2022
• Figure 5.4 European Antibacterial Drugs Market Shares by Country, 2010
• Figure 5.5 European Antibacterial Drugs Market: Revenue Forecasts by Country, 2010-2022
• Figure 5.6 US Antibacterial Drugs Market: Revenue Forecast, 2010-2022
• Figure 5.7 Chinese Antibacterial Drugs Market: Revenue Forecast, 2010-2022
• Figure 5.8 Japanese Antibacterial Drugs Market: Revenue Forecast, 2010-2022
• Figure 5.9 Indian Antibacterial Drugs Market: Revenue Forecast, 2010-2022
• Figure 5.10 Brazilian Antibacterial Drugs Market: Revenue Forecast, 2010-2022
• Figure 7.1 Non-Inferiority Trials and Biocreep: A Worst Case Scenario
• Figure 9.1 Antibacterial Drugs Market: Revenues by Class, 2010, 2016 and 2022
• Figure 9.2 Fate of the 2010 Top 20 Antibacterial Drugs: Revenues, 2010, 2016 and 2022

Companies Listed

Press Release

全球的抗菌藥市場、在2016年預計達438億美金

相關商品

感染疾病相關市場調查報告書

抗病毒藥物的市場 (∼2017年):抵消HIV治療藥物市場上非專利藥品影響的高價的複合治療藥物的接受度增加
Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market
價格 : US $ 3500
出版日期 : 2012年04月

抗病毒療法：技術、市場、企業
Antiviral Therapeutics - technologies, markets and companies
價格 : US $ 3500
出版日期 : 2012年04月

皰疹市場(∼2018年):為求與其他競爭公司有所差異的非專利藥品，而採用新的給藥技術
Herpes Market to 2018 - Genericization Compels Competitors Seeking Differentiation to Adopt Novel Drug Delivery Technologies
價格 : US $ 3500
出版日期 : 2012年04月

Visiongain發行的製藥相關市場調查報告書

醫藥品主要企業系列:前50大學名藥廠商企業 2012-2022年

Pharma Leader Series: Top 50 Generic Drug Manufacturers 2012-2022

價格 : US $ 2642

出版日期 : 2012年03月

眼科用醫藥品的全球市場預測

Ophthalmic Drugs: World Market Prospects 2012-2022

價格 : US $ 2642

出版日期 : 2012年03月

主要抗癌藥及相關市場:2012-2022年

Leading Anti-Cancer Drugs and Associated Market 2012-2022

價格 : US $ 2642

出版日期 : 2012年02月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!